25 May 2012
Atomoxetine (brand name Strattera) is used to treat attention-deficit and hyperactivity disorder (ADHD) in children aged over 6 years and adolescents. Some patients may need to continue treatment into adulthood.
Many patients taking atomoxetine experience small increases in heart rate and blood pressure that are not clinically relevant. However, a review of data has found that approximately 10% of patients experience larger and more prolonged increases in heart rate and blood pressure, which may have clinical implications in some patient groups.
Atomoxetine should not be used in patients with pre-existing severe heart or circulation problems (including disorders of the blood circulation system in the brain). Health professionals should monitor blood pressure and heart rate in all patients receiving atomoxetine during the course of their treatment.
In patients without pre-existing heart or circulation problems, the benefits of atomoxetine outweigh the risks.
The results of the review are summarised in this Public Assessment Report.
This report presents the evidence that was available when the regulatory decision was made, showing a ‘snapshot’ of the clinical landscape at the time. However, any advice in this report remains current unless it is superseded by a more recent report (where relevant, this is indicated).